Edition:
United States

Theravance Biopharma Inc (TBPH.OQ)

TBPH.OQ on NASDAQ Stock Exchange Global Market

27.95USD
23 Feb 2018
Change (% chg)

$0.91 (+3.37%)
Prev Close
$27.04
Open
$27.10
Day's High
$28.00
Day's Low
$26.50
Volume
69,582
Avg. Vol
68,203
52-wk High
$43.30
52-wk Low
$22.94

Chart for

About

Theravance Biopharma, Inc. is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company's pipeline of internally discovered product... (more)

Overall

Beta: 1.89
Market Cap(Mil.): $1,512.19
Shares Outstanding(Mil.): 54.10
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 30.96 16.59
EPS (TTM): -- -- --
ROI: -- 14.08 35.07
ROE: -- 15.71 17.79

BRIEF-Theravance Biopharma And Mylan Announce FDA Acceptance Of New Drug Application For Revefenacin

* THERAVANCE BIOPHARMA AND MYLAN ANNOUNCE FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR REVEFENACIN (TD-4208) IN ADULTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Jan 29 2018

BRIEF-Theravance, Mylan Announce FDA Acceptance Of Marketing Application For Revefenacin

* THERAVANCE BIOPHARMA AND MYLAN ANNOUNCE FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR REVEFENACIN (TD-4208) IN ADULTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE Source text for Eikon: Further company coverage:

Jan 29 2018

BRIEF-Theravance Biopharma ‍Files Supplemental NDA With U.S. FDA For Use Of Trelegy Ellipta​

* THERAVANCE BIOPHARMA HIGHLIGHTS SUBMISSION OF LANDMARK IMPACT DATA TO FDA TO SUPPORT EXPANDED LABEL FOR TRELEGY ELLIPTA

Nov 28 2017

BRIEF-Theravance Biopharma highlights marketing authorization in Europe for Trelegy Ellipta as once-daily single inhaler triple therapy for the treatment of COPD

* Theravance Biopharma highlights marketing authorization in Europe for Trelegy Ellipta as once-daily single inhaler triple therapy for the treatment of COPD Source text for Eikon: Further company coverage:

Nov 16 2017

BRIEF-Theravance Biopharma and Mylan submit marketing application to FDA for revefenacin

* Theravance Biopharma and Mylan submit new drug application to FDA for revefenacin (TD-4208) in adults with chronic obstructive pulmonary disease

Nov 13 2017

BRIEF-Theravance Biopharma posts Q3 loss of $1.27 per share

* Theravance biopharma, inc. Reports third quarter 2017 financial results and provides business update

Nov 07 2017

BRIEF-Theravance Biopharma and Mylan reports positive Phase 3 data for Revefenacin

* Theravance Biopharma and mylan report additional positive phase 3 data for Revefenacin (TD-4208) in multiple presentations at 2017 Chest Annual Meeting

Nov 01 2017

BRIEF-Theravance Biopharma reports positive new data from multiple studies of VIBATIV at IDWeek 2017

* Theravance Biopharma reports positive new data from multiple studies of VIBATIV (telavancin) at IDWeek 2017

Oct 09 2017

BRIEF-Theravance Biopharma highlights positive results from impact study of Trelegy Ellipta

* Theravance Biopharma highlights positive headline results from impact study of Trelegy Ellipta announced by Glaxosmithkline and Innoviva

Sep 20 2017

BRIEF-Theravance Biopharma highlights approval of trelegy ellipta for treatment of appropriate patients with COPD in the U.S.

* Theravance Biopharma highlights approval of trelegy ellipta (closed triple) as the first once-daily single inhaler triple therapy for the treatment of appropriate patients with COPD in the US

Sep 19 2017

Competitors

  Price Chg
Merck & Co., Inc. (MRK.N) $54.87 +0.30
The Medicines Company (MDCO.OQ) $31.07 +1.24
GlaxoSmithKline plc (GSK.L) 1,296.00 -7.00
AstraZeneca plc (AZN.L) 4,752.00 -20.00
Novartis AG (NOVN.S) CHF79.38 -0.60

Earnings vs. Estimates